https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:35877 Wed 26 Aug 2020 10:25:47 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55346 Wed 22 May 2024 12:26:00 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28828 V600E mutation, is one of the key alterations in melanoma. Accordingly, two BRAF inhibitors (BRAFi), vemurafenib and dabrafenib are utilized to treat melanoma and resulted in an excellent clinical outcome. However, the clinical success is not long-lasting, and the BRAFi resistance and disease progression inevitably occurs in nearly all patients. Endoplasmic reticulum stress-induced unfolded protein response and autophagy have emerged as potential pro-survival mechanisms adopted by melanoma cells in response to BRAFi. In this review, we discuss the role of unfolded protein response and autophagy that are implicated in the development of BRAFi-resistant melanoma and the corresponding strategy aiming at overcoming the intractable clinical problem.]]> Wed 19 Jan 2022 15:18:22 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24957 in vivo and assessed for possible clinical applications.]]> Thu 27 Jan 2022 15:58:35 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7006 Sat 24 Mar 2018 08:37:51 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:8335 Sat 24 Mar 2018 08:37:01 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20859 Sat 24 Mar 2018 08:02:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47533 Mon 23 Jan 2023 12:22:34 AEDT ]]>